Loading asset research
Kyntra Bio Inc. Common Stock
KYNBNasdaq · USD · StocksQuote as of · Exchange session not verified$7.97
-0.06%
Today
KYNB
Loading 1D prices…
Market cap
$32.3M
Volume
9.7K
52w high
$12.5852w low
$6.32Company profile
Kyntra Bio Inc. Common Stock
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
San Francisco, CA, United States
Employees
34
Fiscal year end
1231
CIK
921299
Session & valuation
Open$8.18
Previous close$7.97
Day high$8.25
Day low$7.92
30-day avg. volume17.7K
Outstanding shares4M
Diluted EPS$45.37
Latest annual period
P/E (trailing)0.18
P/E (forward)-0.56
Price / book-1.07
Beta1.06
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| CNTXContext Therapeutics Inc. Common Stock | $32.2M | $0.00 | — | -$0.38 | -0.63% | Buy |
| RMTIRockwell Medical Inc. Common Stock | $32.1M | $69.3M | -7.67% | -$0.15 | +1.61% | Buy |
| NXTCNextCure Inc. Common Stock | $32M | $0.00 | — | -$19.65 | -4.24% | Buy |
| MIRAMIRA Pharmaceuticals Inc. Common Stock | $32.5M | $0.00 | — | -$1.35 | -1.90% | Buy |
| CPHIChina Pharma Holdings Inc. Common Stock | $32.7M | $4.1M | -76.91% | -$0.74 | 0.00% | Unrated |